Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Radiographs
2.3. Ultrasound
2.4. Laboratory Measurements
2.5. Luminex Technology
2.6. Statistical Analyses
3. Results
3.1. Characteristics of the Study Population
3.2. Inflammatory Mediators are Elevated in Patients with Hand Osteoarthritis
3.3. Inflammatory Mediators in Non-Erosive and Erosive Subgroups of Hand Osteoarthritis
3.4. The Correlation between Inflammatory Mediators and Clinical Manifestations
3.5. Osteoarthritis at Additional Joint Sites and Its Influence on the Levels of Inflammatory Mediators
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kloppenburg, M.; Berenbaum, F. Osteoarthritis year in review 2019: Epidemiology and therapy. Osteoarthr. Cartil. 2020, 28, 242–248. [Google Scholar] [CrossRef] [Green Version]
- James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [Google Scholar] [CrossRef] [Green Version]
- Kalichman, L.; Hernández-Molina, G. Hand osteoarthritis: An epidemiological perspective. Semin. Arthritis Rheum. 2010, 39, 465–476. [Google Scholar] [CrossRef] [PubMed]
- Mathiessen, A.; Conaghan, P.G. Synovitis in osteoarthritis: Current understanding with therapeutic implications. Arthritis Res. 2017, 19, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gazeley, D.J.; Yeturi, S.; Patel, P.J.; Rosenthal, A.K. Erosive osteoarthritis: A systematic analysis of definitions used in the literature. Semin. Arthritis Rheum. 2016, 46, 395–403. [Google Scholar] [CrossRef]
- Hurnakova, J.; Hulejová, H.; Zavada, J.; Hánová, P.; Komarc, M.; Mann, H.; Klein, M.; Šléglová, O.; Olejárová, M.; Forejtova, S.; et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. PLoS ONE 2017, 12, e0183420. [Google Scholar] [CrossRef] [Green Version]
- Haugen, I.K.; Slatkowsky-Christensen, B.; Bøyesen, P.; Sesseng, S.; Van Der Heijde, D.; Kvien, T.K. MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann. Rheum. Dis. 2016, 75, 117–123. [Google Scholar] [CrossRef]
- Haugen, I.K.; Mathiessen, A.; Slatkowskychristensen, B.; Magnusson, K.; Bøyesen, P.; Sesseng, S.; Van Der Heijde, D.; Kvien, T.K.; Hammer, H.B. Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: Is erosive hand osteoarthritis a separate inflammatory phenotype? Osteoarthr. Cartil. 2016, 24, 647–654. [Google Scholar] [CrossRef] [Green Version]
- Kortekaas, M.; Kwok, W.Y.; Reijnierse, M.; Huizinga, T.W.J.; Kloppenburg, M. In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Ann. Rheum. Dis. 2012, 72, 930–934. [Google Scholar] [CrossRef]
- Chow, Y.Y.; Chin, K.-Y. The Role of inflammation in the pathogenesis of osteoarthritis. Mediat. Inflamm. 2020, 2020, 1–19. [Google Scholar] [CrossRef] [Green Version]
- Scanzello, C.R. Chemokines and inflammation in osteoarthritis: Insights from patients and animal models. J. Orthop. Res. 2017, 35, 735–739. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giordano, R.; Petersen, K.K.; Andersen, H.H.; Simonsen, O.; Arendt-Nielsen, L. Serum inflammatory markers in patients with knee osteoarthritis. Clin. J. Pain 2020, 36, 229–237. [Google Scholar] [CrossRef]
- Zhao, X.; Yang, Z.; Zhang, Z.; Kang, Y.; Huang, G.; Wang, S.; Huang, H.; Liao, W.; Zhang, Z. CCL3 serves as a potential plasma biomarker in knee degeneration (osteoarthritis). Osteoarthr. Cartil. 2015, 23, 1405–1411. [Google Scholar] [CrossRef] [Green Version]
- Funck-Brentano, T.; Nethander, M.; Movérare-Skrtic, S.; Richette, P.; Ohlsson, C. Causal factors for knee, hip, and hand osteoarthritis: A Mendelian randomization study in the UK biobank. Arthritis Rheumatol. 2019, 71, 1634–1641. [Google Scholar] [CrossRef] [Green Version]
- Van Delft, M.A.M.; Van Beest, S.; Kloppenburg, M.; Trouw, L.A.; Ioan-Facsinay, A. Presence of autoantibodies in erosive hand osteoarthritis and association with clinical presentation. J. Rheumatol. 2018, 46, 101–105. [Google Scholar] [CrossRef]
- Altman, R.; Alarcon, G.; Appelrouth, D.; Bloch, D.; Borenstein, D.; Brandt, K.; Brown, C.; Cooke, T.D.; Daniel, W.; Gray, R.; et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990, 33, 1601–1610. [Google Scholar] [CrossRef] [PubMed]
- Bellamy, N.; Campbell, J.; Haraoui, B.; Gerecz-Simon, E.; Buchbinder, R.; Hobby, K.; MacDermid, J. Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: An evaluation of reliability, validity and responsiveness. Osteoarthr. Cartil. 2002, 10, 863–869. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dreiser, R.L.; Maheu, E.; Guillou, G.B.; Caspard, H.; Grouin, J.M. Validation of an algofunctional index for osteoarthritis of the hand. Rev. Rhum. Engl. Ed. 1995, 62, 43S–53S. [Google Scholar] [PubMed]
- Kellgren, J.H.; Lawrence, J.S. Radiological assessment of osteo-arthrosis. Ann. Rheum. Dis. 2008, 16, 494–502. [Google Scholar] [CrossRef] [Green Version]
- Kallman, D.A.; Wigley, F.M.; Scott, W.W.; Hochberg, M.C.; Tobin, J.D. New radiographic grading scales for osteoarthritis of the hand. Reliability for determining prevalence and progression. Arthritis Rheum. 1989, 32, 1584–1591. [Google Scholar] [CrossRef]
- Kropáčková, T.; Šléglová, O.; Růžičková, O.; Vencovský, J.; Pavelka, K.; Šenolt, L. Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskelet. Disord. 2018, 19, 264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hurnakova, J.; Zavada, J.; Hánová, P.; Hulejová, H.; Klein, M.; Mann, H.; Šléglová, O.; Olejárová, M.; Forejtova, S.; Růžičková, O.; et al. Serum calprotectin (S100A8/9): An independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res. 2015, 17, 252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020. [Google Scholar]
- Grömping, U. Inference with linear equality and inequality constraints UsingR: The Packageic.infer. J. Stat. Softw. 2010, 33, 1–31. [Google Scholar] [CrossRef]
- Wickham, H.; Averick, M.; Bryan, J.; Chang, W.; McGowan, L.D.; François, R.; Grolemund, G.; Hayes, A.; Henry, L.; Hester, J.; et al. Welcome to the Tidyverse. J. Open Source Softw. 2019, 4, 1686. [Google Scholar] [CrossRef]
- Venables, W.N.; Ripley, B.D. Modern Applied Statistics with S-Plus; Statistics and Computing; Springer New York: New York, NY, USA, 2002; ISBN 978-1-4419-3008-8. [Google Scholar]
- Wickham, H. ggplot2; Springer New York: New York, NY, USA, 2009; ISBN 978-0-387-98140-6. [Google Scholar]
- Wittoek, R.; Carron, P.; Verbruggen, G. Structural and inflammatory sonographic findings in erosive and non-erosive osteoarthritis of the interphalangeal finger joints. Ann. Rheum. Dis. 2010, 69, 2173–2176. [Google Scholar] [CrossRef] [Green Version]
- Punzi, L.; Ramonda, R.; Oliviero, F.; Sfriso, P.; Mussap, M.; Plebani, M.; Podswiadek, M.; Todesco, S. Value of C reactive protein in the assessment of erosive osteoarthritis of the hand. Ann. Rheum. Dis. 2005, 64, 955–957. [Google Scholar] [CrossRef]
- Dolzani, P.; Assirelli, E.; Pulsatelli, L.; Addimanda, O.; Mancarella, L.; Peri, G.; Mantovani, A.; Facchini, A.; Meliconi, R. Systemic inflammation and antibodies to citrullinated peptides in hand osteoarthritis. Clin. Exp. Rheumatol. 2011, 29, 1006–1009. [Google Scholar]
- Hulejová, H.; Barešová, V.; Klézl, Z.; Polanská, M.; Adam, M.; Šenolt, L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 2007, 38, 151–156. [Google Scholar] [CrossRef]
- Nees, T.A.; Rosshirt, N.; Zhang, J.A.; Reiner, T.; Sorbi, R.; Tripel, E.; Walker, T.; Schiltenwolf, M.; Hagmann, S.; Moradi, B. Synovial cytokines significantly correlate with osteoarthritis-related knee pain and disability: Inflammatory mediators of potential clinical relevance. J. Clin. Med. 2019, 8, 1343. [Google Scholar] [CrossRef] [Green Version]
- Snelling, S.J.B.; Bas, S.; Puskas, G.J.; Dakin, S.G.; Suva, D.; Finckh, A.; Gabay, C.; Hoffmeyer, P.; Carr, A.J.; Lubbeke-Wolff, A. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS ONE 2017, 12, e0175109. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.-C.; Hsu, C.-J.; Fong, Y.-C.; Chuang, S.-M.; Tang, C. CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. Biochim. Biophys. Acta (BBA)-Bioenerg. 2013, 1833, 1114–1124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Houard, X.; Goldring, M.B.; Berenbaum, F. Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. Curr. Rheumatol. Rep. 2013, 15, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berenbaum, F.; Griffin, T.M.; Liu-Bryan, R. Review: Metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017, 69, 9–21. [Google Scholar] [CrossRef] [PubMed]
- Hsu, Y.-H.; Hsieh, M.-S.; Liang, Y.-C.; Li, C.-Y.; Sheu, M.-T.; Chou, D.-T.; Chen, T.-F.; Chen, C.-H. Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J. Cell. Biochem. 2004, 93, 929–939. [Google Scholar] [CrossRef] [PubMed]
- Baba, T.; Mukaida, N. Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis. Mol. Cell. Oncol. 2014, 1, e29899. [Google Scholar] [CrossRef]
- Ibi, M.; Horie, S.; Kyakumoto, S.; Chosa, N.; Yoshida, M.; Kamo, M.; Ohtsuka, M.; Ishisaki, A. Cell-cell interactions between monocytes/macrophages and synoviocyte-like cells promote inflammatory cell infiltration mediated by augmentation of MCP-1 production in temporomandibular joint. Biosci. Rep. 2018, 38. [Google Scholar] [CrossRef] [Green Version]
- He, Y.; Liang, X.; Wu, X.; Meng, C.; Wu, B.; Fu, D.; Jin, S.; Yang, S.; Wang, H. Association between interleukin 8−251 A/T and +781 C/T polymorphisms and osteoarthritis risk. Immunol. Lett. 2014, 162, 207–211. [Google Scholar] [CrossRef]
- Oliviero, F.; Ramonda, R.; Scanu, A.; Galozzi, P.; Favero, M.; Punzi, L. Levels of inflammatory cytokines and metalloproteinases are increased in knee synovial fluid of patients with concomitant erosive hand osteoarthritis. Clin. Exp. Rheumatol 2020, 38, 800. [Google Scholar]
- Meliconi, R.; Pulsatelli, L. Are mechanisms of inflammation joint-specific in osteoarthritis? Rheumatology 2018, 58, 743–745. [Google Scholar] [CrossRef] [Green Version]
- Miyabe, Y.; Lian, J.; Miyabe, C.; Luster, A.D. Chemokines in rheumatic diseases: Pathogenic role and therapeutic implications. Nat. Rev. Rheumatol. 2019, 15, 731–746. [Google Scholar] [CrossRef]
- Baraliakos, X.; Gensler, L.S.; D’Angelo, S.; Iannone, F.; Favalli, E.G.; De Peyrecave, N.; Auteri, S.E.; Caporali, R. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. Ther. Adv. Musculoskelet. Dis. 2020, 12, 1759720x2090604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmid, A.S.; Neri, D. Advances in antibody engineering for rheumatic diseases. Nat. Rev. Rheumatol. 2019, 15, 197–207. [Google Scholar] [CrossRef] [PubMed]
- Taylor, P. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 2010, 10, 308–315. [Google Scholar] [CrossRef] [PubMed]
- Aitken, D.; Laslett, L.L.; Pan, F.; Haugen, I.K.; Otahal, P.; Bellamy, N.; Bird, P.; Jones, G. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis-the HUMOR trial. Osteoarthr. Cartil. 2018, 26, 880–887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Philp, A.M.; Davis, E.T.; Jones, S.W. Developing anti-inflammatory therapeutics for patients with osteoarthritis. Rheumatology 2016, 56, kew278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kloppenburg, M.; Peterfy, C.; Haugen, I.K.; Kroon, F.; Chen, S.; Wang, L.; Liu, W.; Levy, G.; Fleischmann, R.M.; Berenbaum, F.; et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann. Rheum. Dis. 2019, 78, 413–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shin, K.; Kim, J.W.; Moon, K.W.; Yang, J.A.; Lee, E.Y.; Song, Y.W.; Lee, E.B. The efficacy of Diacerein in hand osteoarthritis: A double-blind, randomized, placebo-controlled study. Clin. Ther. 2013, 35, 431–439. [Google Scholar] [CrossRef]
HOA Patients (n = 104) | Patients with Non-Erosive HOA (n = 50) | Patients with Erosive HOA (n = 54) | Healthy Controls (n = 49) | |
---|---|---|---|---|
Female, n (%) | 90 (87) | 43 (86) | 47 (87) | 42 (86) |
Age [years], Mean ± SD | 66.3 ± 8.2 | 64.3 ± 7.3 | 67.6 ± 8.6 | 62.6 ± 8.2 |
CRP [mg/L], Median (IQR) | 3.2 (1–3.5) | 2.9 (0.9–3) | 3.4 (1.1–3.5) | 2.3 (0.9–3) |
BMI, Mean ± SD | 27.0 ± 3.5 | 26.6 ± 3.9 | 27.4 ± 4.3 | 26.4 ± 3.7 |
Clinically tender joints [count], Median (IQR) | 6 (2–9) | 5 (2–8) | 6 (2–9) | - |
Clinically swollen joints [count], Median (IQR) | 5 (1–7) | 5 (17) | 5 (1–7) | - |
Algofunctional index, Median (IQR) | 19 (14–22) | 17 (13–21) | 19 (14–24) * | - |
AUSCAN—total, Mean ± SD | 22.5 ± 10.4 | 20.3 ± 9.1 | 23.9 ± 11 | - |
AUSCAN—pain, Mean ± SD | 8.4 ± 4.2 | 7.5 ± 3.8 | 9 ± 4.4 * | - |
AUSCAN—stiffness, Mean ± SD | 1.9 ± 0.9 | 1.9 ± 0.9 | 2 ± 0.9 | - |
AUSCAN—function, Median (IQR) | 12 (6–17) | 10.9 (6–15.8) | 12.8 (7–18) | - |
VAS, Median (IQR) | 44.6 (28–59) | 42.2 (30–54.5) | 46.7 (26–67) | - |
HAQ, Median (IQR) | 0.8 (0.4–1.3) | 0.8 (0.4–1.1) | 0.9 (0.4–1.3) | - |
GS synovitis—total, Median (IQR) | 7.5 (1–12.5) | 5 (0–5.5) | 9.3 (2–15) *** | - |
GS synovitis—joint count, Median (IQR) | 2 (0–3) | 1.4 (0-2) | 2.5 (0–4) *** | - |
PD synovitis—total, Median (IQR) | 5 (1–8) | 4 (0–6) | 7 (2–11) *** | - |
PD synovitis—joint count, Median (IQR) | 2 (0–3) | 1 (0–2) | 2 (0–3) *** | - |
Knee OA [count] n (%) | 30 (29) | 12 (24) | 18 (33) | - |
A | B | ||||||
---|---|---|---|---|---|---|---|
Mediators | p-Value | Effect Size (95% CI) | Log2fc | Mediators | p-Value | Effect Size (95% CI) | Log2fc |
TNF | <0.001 | 0.314 (0.200–0.431) | 1.14 | RANTES | 0.074 | 0.019 (−0.01–0.113) | 0.20 |
MIP-1β | <0.001 | 0.314 (0.200–0.430) | 1.27 | PDGF-bb | 0.123 | 0.012 (−0.01–0.1) | 0.25 |
IP-10 | <0.001 | 0.258 (0.147–0.376) | 1.23 | MCP-1 | 0.154 | 0.008 (−0.01–0.09) | 0.49 |
MIP-1α | <0.001 | 0.218 (0.112–0.337) | 1.18 | Eotaxin | 0.217 | 0.003 (−0.01–0.079) | 0.42 |
Eotaxin | <0.001 | 0.182 (0.082–0.299) | 1.12 | TNF | 0.280 | 0.000 (−0.01–0.072) | 0.15 |
IL-8 | <0.001 | 0.159 (0.064–0.275) | 0.93 | MIP-1α | 0.382 | −0.001 (−0.01–0.069) | −0.09 |
MCP-1 | <0.001 | 0.105 (0.027–0.213) | 0.92 | IL-4 | 0.455 | −0.005 (−0.01–0.056) | 0.12 |
IL-17 | 0.008 | 0.049 (−0.004–0.148) | 0.56 | IL-9 | 0.555 | −0.007 (−0.01–0.051) | 0.11 |
PDGF-bb | 0.009 | 0.042 (−0.003–0.129) | −0.49 | IL-8 | 0.566 | −0.007 (−0.01–0.047) | 0.18 |
IL-1RA | 0.029 | 0.025 (−0.007–0.102) | 0.53 | IL-1ra | 0.594 | −0.008 (−0.01–0.045) | 0.00 |
IL-1β | 0.03 | 0.032 (−0.01–0.134) | 0.42 | MIP-1β | 0.628 | −0.008 (−0.01–0.044) | −0.01 |
IL-9 | 0.244 | 0.003 (−0.007–0.06) | −0.27 | IL-1β | 0.697 | −0.014 (−0.016–0.055) | −0.58 |
IL-4 | 0.398 | −0.003 (−0.007–0.042) | −0.39 | IL-17 | 0.763 | −0.011 (−0.013–0.043) | −0.18 |
IFN-γ | 0.533 | −0.004 (−0.008–0.046) | 0.13 | IP-10 | 0.846 | −0.009 (−0.01–0.026) | 0.00 |
RANTES | 0.671 | −0.005 (−0.007–0.033) | 0.63 | IFN-γ | 0.922 | −0.011 (−0.012–0.027) | −0.29 |
A | ||||||
---|---|---|---|---|---|---|
Mediators | Clinically Tender Joints | Clinically Swollen Joints | GS Synovitis | PD Synovitis | GS Positive Joints | PD Positive Joints |
Eotaxin | −0.02 | −0.03 | −0.26 | −0.13 | −0.27 | −0.14 |
IFN-γ | 0.08 | 0.15 | −0.06 | −0.12 | −0.06 | −0.12 |
IL-17 | 0.10 | 0.14 | −0.04 | 0.01 | −0.02 | 0.03 |
IL-1β | −0.16 | 0.02 | −0.12 | −0.15 | −0.13 | −0.16 |
IL-1RA | 0.04 | 0.03 | −0.19 | 0.06 | −0.18 | 0.05 |
IL-4 | 0.03 | 0.02 | −0.11 | 0.02 | −0.10 | 0.00 |
IL-8 | 0.00 | −0.10 | −0.07 | −0.09 | −0.06 | −0.10 |
IL-9 | −0.06 | −0.01 | −0.16 | 0.13 | −0.16 | 0.14 |
IP-10 | 0.04 | 0.02 | −0.22 | −0.14 | −0.20 | −0.14 |
MCP-1 | −0.10 | −0.12 | −0.36 * | −0.17 | −0.34 * | −0.18 |
MIP-1α | −0.07 | −0.09 | −0.28 | −0.16 | −0.26 | −0.15 |
MIP-β | −0.16 | −0.18 | −0.19 | −0.06 | −0.17 | −0.06 |
PDGF-bb | −0.09 | −0.07 | −0.27 | −0.06 | −0.26 | −0.06 |
RANTES | −0.16 | −0.06 | −0.29 | −0.05 | −0.26 | −0.05 |
TNF | −0.16 | −0.11 | −0.22 | −0.16 | −0.19 | −0.16 |
B | ||||||
Mediators | Clinically Tender Joints | Clinically Swollen Joints | GS Synovitis | PD Synovitis | GS Positive Joints | PD Positive Joints |
Eotaxin | 0.35 * | 0.35 * | 0.38 * | −0.03 | 0.43 * | 0.00 |
IFN-γ | 0.24 | 0.20 | 0.21 | −0.01 | 0.21 | 0.02 |
IL-17 | −0.10 | −0.02 | −0.22 | −0.21 | −0.19 | −0.24 |
IL-1β | 0.17 | 0.22 | 0.19 | −0.09 | 0.23 | −0.07 |
IL-1RA | 0.23 | 0.26 | 0.35 * | 0.07 | 0.38 * | 0.12 |
IL-4 | 0.15 | 0.23 | 0.12 | −0.13 | 0.19 | −0.10 |
IL-8 | 0.23 | 0.20 | 0.30 * | −0.01 | 0.32 * | 0.00 |
IL-9 | 0.05 | 0.01 | 0.14 | −0.11 | 0.18 | −0.09 |
IP-10 | 0.29 | 0.25 | 0.43 * | −0.01 | 0.45 * | 0.04 |
MCP-1 | 0.30 * | 0.31 * | 0.40 * | 0.04 | 0.43 * | 0.06 |
MIP-1α | 0.20 | 0.25 | 0.35 * | 0.05 | 0.35 * | 0.04 |
MIP-β | 0.31 * | 0.30 * | 0.50 * | 0.03 | 0.48 * | 0.06 |
PDGF-bb | 0.21 | 0.18 | 0.44 * | 0.08 | 0.44 * | 0.09 |
RANTES | 0.28 | 0.25 | 0.43 * | 0.10 | 0.43 * | 0.14 |
TNF | 0.40 * | 0.32 * | 0.57 * | 0.00 | 0.57 * | 0.04 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baloun, J.; Kropáčková, T.; Hulejová, H.; Tomčík, M.; Růžičková, O.; Šléglová, O.; Gatterová, J.; Vencovský, J.; Pavelka, K.; Šenolt, L. Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules 2021, 11, 4. https://doi.org/10.3390/biom11010004
Baloun J, Kropáčková T, Hulejová H, Tomčík M, Růžičková O, Šléglová O, Gatterová J, Vencovský J, Pavelka K, Šenolt L. Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules. 2021; 11(1):4. https://doi.org/10.3390/biom11010004
Chicago/Turabian StyleBaloun, Jiří, Tereza Kropáčková, Hana Hulejová, Michal Tomčík, Olga Růžičková, Olga Šléglová, Jindřiška Gatterová, Jiří Vencovský, Karel Pavelka, and Ladislav Šenolt. 2021. "Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis" Biomolecules 11, no. 1: 4. https://doi.org/10.3390/biom11010004
APA StyleBaloun, J., Kropáčková, T., Hulejová, H., Tomčík, M., Růžičková, O., Šléglová, O., Gatterová, J., Vencovský, J., Pavelka, K., & Šenolt, L. (2021). Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules, 11(1), 4. https://doi.org/10.3390/biom11010004